# Sonelokimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sonelokimab

> The next catalyst for sonelokimab, sponsored by MoonLake Immunotherapeutics (MLTX), is its interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for sonelokimab?

The next catalyst for sonelokimab, sponsored by MoonLake Immunotherapeutics (MLTX), is its interim data readout, Q1 2027. Press release filed with the SEC (EX-99): "•Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol" [Calendar and source filings](https://sec-api.dev/pdufa/sonelokimab)

Source: Press release filed with the SEC (EX-99), accession 0001821586-26-000013, https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/sonelokimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | sonelokimab |
| Codes |  |
| Sponsor | MoonLake Immunotherapeutics (MLTX) https://sec-api.dev/companies/mltx/catalysts |
| Indications | [moderate-to-severe hidradenitis suppurativa](https://sec-api.dev/indications/moderate-to-severe-hidradenitis-suppurativa), [Hidradenitis Suppurativa](https://sec-api.dev/indications/hidradenitis-suppurativa), [Arthritis, Psoriatic](https://sec-api.dev/indications/arthritis-psoriatic) |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### August 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06411379

### Sep 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2025-08-05, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000016): "•Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026" https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/moonlake-pressreleasexq220.htm

### September 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06411899 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06411899

### November 5, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000021): "MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab" https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm

### February 18, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-02-23, last confirmed 2026-02-23.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-018967): "Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results" https://www.sec.gov/Archives/edgar/data/1821586/000121390026018967/ea027791001ex99-1_moonlake.htm

### May 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06641076 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06641076

### Q3 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000021): "The Company expects to commence a Phase 3 clinical trial in PPP in Q3 2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm

### August 10, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-11-05, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-086939): "MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-na&iuml;ve adults with active psoriatic arthritis (PsA) and reported second quarter 2026 financial results." https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000021): "The trial is expected to enroll a total of 30-35 patients and topline results are expected to become available in 2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm

### August 10, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-08-10, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-086939): "MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results" https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm

### Sep 2026: NDA/BLA acceptance

- Status: scheduled. Date confidence: month.
- First seen 2026-05-11, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000005): "•With no remaining gaps identified, the pre-BLA process for HS is complete, and the BLA submission to the FDA is planned for the end of September 2026; acceptance, including a decision on Priority Review designation associated with the inclusion of VELA-TEEN adolescent data, is expected by end of November 2026" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/moonlake-pressreleasexq120.htm

### September 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06768671

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-06-22, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06768671
- Press release filed with the SEC (EX-99) (accession 0001213900-26-070362): "In this session, MoonLake's CEO, Jorge Santos da Silva, CSO, Kristian Reich, and CFO, Matthias Bodenstedt, will present the final Week 52 data from the Phase 3 VELA program in HS and provide an update on the VELA-TEEN clinical trial in adolescent HS, a recap of the proposed label, the Company's view on its commercialization plan, as well as an outlook on H2 2026 events, including the readout of IZAR-1 Phase 3 trial in psoriatic arthritis (PsA)." https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea029539901ex99-1.htm

### September 30, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: moderate-to-severe hidradenitis suppurativa.
- First seen 2025-08-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "On September 30, 2026, the Company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval of sonelokimab (SLK) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000021): "The increase of $10.8 million was driven by increases in expenses with contract research organizations and contract manufacturing organizations, as well as consulting expenses and personnel-related costs, all to support the further ramp-up of MoonLake's clinical trials and preparations for the anticipated submission of the BLA for sonelokimab in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-25-000016): "The increase of $13.3 million was driven by increases in expenses with contract research organizations and contract manufacturing organizations, as well as consulting expenses and personnel-related costs, all to support the further ramp-up of MoonLake's clinical trials and preparations for the anticipated submission of the BLA for sonelokimab in mid-2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/moonlake-pressreleasexq220.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-086939): "o End Sep. 2026: Expected submission of Biologics License Application (BLA)" https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000005): "Based on this feedback, MoonLake expects to submit the BLA for SLK in adult and adolescent HS to the FDA at the end of September 2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/moonlake-pressreleasexq120.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-002344): "The preparations for the submission of the BLA continue as planned and are on track for submission in H2 2026." https://www.sec.gov/Archives/edgar/data/1821586/000121390026002344/ea027225201ex99-1_moonlake.htm

### Nov 2026: trial start

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "The Company expects to commence enrollment in the Phase 3 NOVA trial as per plans in November 2026." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "•PPP: Expected to commence enrollment for the NOVA Phase 3 trial in November 2026" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm

### Nov 2026: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-06-22, last confirmed 2026-06-22.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-070362): "Clarity on the Prescription Drug User Fee Act (PDUFA) date is currently expected by the end of November 2026, concurrent with the FDA's acceptance of the BLA." https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea029539901ex99-1.htm

### Q1 2027: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "•Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "The Company expects to announce initial topline results following a predefined unblinding protocol in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-10, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "◦Expected to conclude VELA-TEEN clinical trial in Q4 2026 and present final topline results at a scientific meeting in the first quarter of 2027" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "◦IZAR-2: Expected to announce Week 16 topline results in Q1 2027 and Week 52 results in Q4 2027" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-086939): "IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027 whereas the IZAR-2 trial (a trial in TNF-refractory patients) is expected to complete enrollment in Q3 2026" https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06641089 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06641089

### Q2 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-04, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001821586-26-000013): "◦IZAR-1: Expected to announce Week 52 topline results in Q2 2027" https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm
- ClinicalTrials.gov: "NCT06641089 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT06641089

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT07223138

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT07223138

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT07007637

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." https://clinicaltrials.gov/study/NCT07007637

## Same indication

- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib) (INSM)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [JNJ-88545223](https://sec-api.dev/pdufa/jnj-88545223) (JNJ)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sonelokimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sonelokimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sonelokimab

```bibtex
@misc{secapidev_pdufa_sonelokimab_20261116,
  title        = {Sonelokimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sonelokimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sonelokimab_20261116","title":"Sonelokimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sonelokimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
